Evidence mapPaperPMID 33925464Full record

ReviewInternational journal of molecular sciences2021

Functions of Thrombospondin-1 in the Tumor Microenvironment.

Sukhbir Kaur, Steven M Bronson, Dipasmita Pal-Nath, Thomas W Miller, David R Soto-Pantoja, David D Roberts

Open access · goldAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 115 papers.

0numbers the graph read from it
0cells of the map it votes in
115citing papers in PubMed
8.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

115 citing papers in PubMed, 161 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. THBS1Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. MacrophageJournal for immunotherapy of cancer · 2026
    Article
  18. Article
  19. Article
  20. Article

55 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Sukhbir KaurLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Steven M BronsonDepartment of Internal Medicine, Section of Molecular Medicine, Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC 27101, USA.
Dipasmita Pal-NathLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.
Thomas W MillerCentre de Recherche en Cancérologie de Marseille, Institut Paoli-Calmettes, 13273 Marseille, France.ORCID 0000-0001-8645-2785
David R Soto-PantojaDepartment of Surgery and Department of Cancer Biology, Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC 27101, USA.
David D RobertsLaboratory of Pathology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD 20892, USA.ORCID 0000-0002-2481-2981
National Cancer Institute · USWake Forest University · USCentre de Recherche en Cancérologie de Marseille · FR

Funding

Laboratory Animal & Comparative Medicine TrainingT32OD010957 · WAKE FOREST UNIVERSITY HEALTH SCIENCES · 2025 to 2025
$372k
Quantitative High Throughput Screening for Small Molecules Targeting CD47 in CancerU01CA218259 · NCI · INSTITUT JEAN PAOLI & IRENE CALMETTES CENTRE REGIONAL DE LUTTE CONTRE LE CANCER · PI Thomas W Miller · 2021 to 2021
$270k
Quantitative High Throughput Screening for Small Molecules Targeting CD47 in CancerR37CA218259 · NCI · INSTITUT JEAN PAOLI & IRENE CALMETTES CENTRE REGIONAL DE LUTTE CONTRE LE CANCER · PI Thomas W Miller · 2023 to 2023
$265k
American Cancer Society 133727-RSG-19-150-01-LIBFondation ARC pour la Recherche sur le Cancer COVID202001312NCI NIH HHS R37 CA218259NCI NIH HHS U01 CA218259NIH HHS CA218259NIH HHS CA249349NIH HHS T32 OD010957NIH HHS T32-OD010957NIH HHS ZIA SC009172
6 · The paper itself

Abstract

The identification of thrombospondin-1 as an angiogenesis inhibitor in 1990 prompted interest in its role in cancer biology and potential as a therapeutic target. Decreased thrombospondin-1 mRNA and protein expression are associated with progression in several cancers, while expression by nonmalignant cells in the tumor microenvironment and circulating levels in cancer patients can be elevated.

Indexed as

NeoplasmsAnimalsCell AdhesionCell MovementHumansIntegrinsMiceNeovascularization, PathologicNeovascularization, PhysiologicThrombospondin 1T-LymphocytesTumor MicroenvironmentIntegrinsThbs1 protein, mouseThrombospondin 1thrombospondin-1, humanangiogenesisautophagyCD36CD47cytotoxic T cellsintegrinsnatural killer cellsnitric oxidetransforming growth factor-β1tumor-initiating cells

Identifiers

PMID33925464
PMCPMC8123789
OpenAlexW3159096236

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.